Cullinan Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGEM research report →
Range $27 – $39
Price Chart
About the company
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology).
- CEO
- Nadim Ahmed
- IPO
- 2021
- Employees
- 109
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on CGEM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.30B
- P/E
- -6.26
- PEG
- -1.99
- P/S
- 0.00
- P/B
- 4.03
- EV/EBITDA
- -5.86
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -52.89%
- ROIC
- -68.50%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-241,648,000
- Net Income
- $-219,879,000-31.4%
- EPS
- $-3.72-19.6%
- OCF Growth
- -21.0%
- FCF Growth
- -21.0%
- 52W High
- $22.54
- 52W Low
- $5.68
- 50D MA
- $17.41
- 200D MA
- $13.77
- Beta
- -0.01
- RSI (14)
- 65
- Avg Volume
- 958.55K
No earnings-call transcripts are available for CGEM yet.
- Free Float
- 71.8%
- Shares Outstanding
- 61.46M
- Float Shares
- 44.16M
of shares held by institutions
177 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bioimpact Capital LLC | 9.73M | ▲ 2.08M |
| Lynx1 Capital Management LP | 8.96M | 0 |
| Bvf Inc/Il | 5.75M | 0 |
| Blackrock, Inc. | 5.23M | ▲ 782.80K |
| Price T Rowe Associates Inc | 3.83M | ▲ 1.80M |
| State Street Corp | 3.67M | ▲ 1.12M |
| Vanguard Group Inc | 3.30M | ▲ 355.18K |
| Kynam Capital Management, LP | 3.11M | 0 |
| Vanguard Capital Management LLC | 2.61M | ▲ 131.03K |
| Rtw Investments, LP | 2.36M | ▲ 658.39K |
| Siren, L.L.C. | 1.89M | ▲ 700.00K |
| Geode Capital Management, LLC | 1.55M | ▲ 179.04K |
Held by 217 ETFs
Biggest fund positions in CGEM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 13, 26 | Michaelson Jennifer | other | 30,000 |
| Aug 13, 26 | Michaelson Jennifer | sell | 30,000 |
| Aug 13, 26 | Michaelson Jennifer | other | 30,000 |
| Jul 6, 26 | Michaelson Jennifer | other | 4,000 |
| Jul 6, 26 | Michaelson Jennifer | sell | 8,000 |
| Jul 6, 26 | Michaelson Jennifer | other | 4,000 |
| Jun 30, 26 | SUMER JACQUELYN L | other | 2,470 |
| Jun 30, 26 | Fenton Mary Kay | other | 1,541 |
| Jun 16, 26 | Rosenberg Anthony | other | 25,319 |
| Jun 16, 26 | Meek David D. | other | 25,319 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CGEM coverage
Recent articles, reports, and earnings notes.
No research on CGEM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CGEM report →Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
businesswire.com · Aug 19
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
benzinga.com · Aug 13
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
businesswire.com · Aug 12
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
globenewswire.com · Aug 6
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
globenewswire.com · Jul 28
Cullinan Therapeutics: Heading Toward Paydirt
seekingalpha.com · Jun 11
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcript
seekingalpha.com · Jun 10
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
globenewswire.com · Jun 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.